Pregnancy: Spedra is not indicated for use in women.
There are no data from the use of avanafil in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition, or postnatal development (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Breast-feeding: There are no data on the use of avanafil during breast-feeding.
Fertility: There was no effect on sperm motility or morphology after single 200 mg oral doses of avanafil in healthy volunteers.
Currently, no data on spermatogenesis on healthy adult males and adult males with mild ED are available.